Please log in to determine if you are eligible to purchase PT Programs.
NGS HEMATOLOGIC MALIGNANCIES - NGSHM
NGSHM
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Procedure Challenges per Shipment Number of Shipments
Next‑generation sequencing 3 Two shipments per year

Additional Information

  • This is a methods‑based proficiency challenge for laboratories performing targeted next‑generation sequencing of genes or mutation hotspots in hematologic malignancies. Laboratories will be asked to identify somatic single nucleotide variants and small insertions or deletions in some of these genes: ASXL1, ATM, BRAF, CALR, CEBPA, CREBBP, CSF3R, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KMT2D, MPL, MYD88, NOTCH1, NPM1, SF3B1, SRSF2, TET2, TP53, U2AF1.
  • This program includes variants present with a variant allele fraction (VAF) potentially as low as 5%.

Program Information

  • Three 1.0‑μg gDNA (50 ng/μL) specimens

Shipping Schedule

  • Shipment A: May 2
  • Shipment B: November 14






Customers Who Bought This Item Also Bought
NGS SOLID TUMOR
VIEW DETAILS >
VARIANT INTERPRETATION ONLY
VIEW DETAILS >